Under the terms of the agreement, I-Mab will assume exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territory. MorphoSys receives
Original Article: I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine
NEXT ARTICLE